OptimizeRx Earnings Call Transcripts
Fiscal Year 2025
-
Q4 and FY2025 results exceeded expectations with strong revenue, margin expansion, and cash flow. 2026 guidance is more conservative due to market softness, but profitability focus and growth in mid-tier clients remain strong. Share repurchase and debt reduction continue.
-
Operational and financial momentum remains strong, with improved revenue visibility and margin expansion driven by subscription-based models and favorable product mix. Guidance is conservative, with stable operating expenses and no contribution from new partnerships like Lamar included.
-
Q2 2025 saw 55% revenue growth and a return to profitability, with gross margin and cash flow both improving. Guidance for 2025 was raised, and strong contracted revenue growth provides visibility, while accelerated debt repayment and a robust digital offering position the company well.
-
Q1 2025 revenue grew 11% year-over-year to $21.9 million, with adjusted EBITDA at $1.5 million and over 80% of full-year revenue already contracted. Guidance was raised to $101–$106 million in revenue and $13–$15 million in adjusted EBITDA, supported by strong pipeline and early subscription model momentum.
Fiscal Year 2024
-
Revenue and adjusted EBITDA exceeded expectations in 2024, driven by DAAP growth and margin expansion. Recurring revenue and customer centricity are strategic priorities, with a three- to five-year path to Rule of 40 and strong contracted revenue visibility for 2025.
-
Q3 revenue rose 30% year-over-year to $21.3M, with strong HCP growth offsetting DTC softness. Updated 2024 guidance calls for $88–$92M revenue and $8–$10M Adjusted EBITDA, as the business shifts to self-service DTC and expands DAP adoption. Four clients are expected to generate over $10M each in 2025.
-
Q2 2024 saw 36% revenue growth and improved margins, but revenue missed expectations due to a delayed $6M DAAP deal, now expected to close in Q3. Strong DAAP adoption, improved KPIs, and robust pipeline support confidence in meeting full-year guidance.